Deferred Tax Assets, Valuation Allowance of Immunovant, Inc. from 31 Dec 2018 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Immunovant, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2018 to 31 Mar 2025.
  • Immunovant, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Mar 2025 was $218,753,000, a 55% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Immunovant, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $218,753,000 +$77,269,000 +55% 31 Mar 2025 10-K 29 May 2025 2025 FY
Q1 2024 $141,484,000 +$49,496,000 +54% 31 Mar 2024 10-K 29 May 2025 2025 FY
Q1 2023 $91,988,000 +$33,284,000 +57% 31 Mar 2023 10-K 29 May 2024 2024 FY
Q1 2022 $58,704,000 +$23,751,000 +68% 31 Mar 2022 10-K 22 May 2023 2023 FY
Q1 2021 $34,953,000 +$15,824,000 +83% 31 Mar 2021 10-K 08 Jun 2022 2022 FY
Q1 2020 $19,129,000 +$10,219,000 +115% 31 Mar 2020 10-K 01 Jun 2021 2020 FY
Q3 2019 $97,000 30 Sep 2019 10-Q 13 Nov 2019 2019 Q3
Q1 2019 $8,910,000 31 Mar 2019 10-K 29 Jun 2020 2019 FY
Q4 2018 $0 31 Dec 2018 10-Q 13 Nov 2019 2019 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.